The Butantan Institute submitted a request to Anvisa (Brazil's National Health Surveillance Agency) on Monday (16) for the registration of its dengue vaccine for use in Brazil. The immunizer was developed by the institute.
If approved, Butantan-DV will become the world's first single-dose vaccine against the disease transmitted by the *Aedes aegypti* mosquito.
This approval is expected to boost population immunization since the current two-dose regimen often results in many people failing to return for the second shot.
The Butantan Institute's vaccine is tetravalent, meaning it is effective against all four dengue virus serotypes present in Brazil — the most common being types 1 and 2.
Clinical trials concluded in June this year. The final phase of testing showed an overall efficacy of 79.5% in preventing the disease with just one dose. The vaccine significantly reduces cases and, in particular, hospitalizations caused by dengue.
The data comes from a two-year follow-up of over 16,000 Brazilians who received the vaccine.